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Will Enhanced Phenotyping Be Necessary for
Future Clinical Trial Success?*Gary S. Francis, MD, Rebecca Cogswell, MD, Thenappan Thenappan, MDH eart failure (HF) is increasing in prevalenceand has a projected disease burden ofmore than 8.1 million patients in the United
States by the year 2030 (1). One-half of the patients
with HF have a reduced ejection fraction (HFrEF),
and the remaining patients present with a preserved
ejection fraction (HFpEF) (2). Both syndromes produce
high mortality and morbidity (1,3). In the case of
HFrEF, pharmacological and device advances over
the last 3 decades have signiﬁcantly improved disease
survival. However, more recent clinical trials in this
group have yielded neutral results (4–8).
There may be several reasons why recent clinical
trials have failed to meet their endpoints. First, the
majority of the patients entering into contemporary
clinical trials with a HFrEF are receiving background
medical therapy for which it is difﬁcult to demonstrate
an incremental clinical beneﬁt. Second, some of these
trials may have been underpowered. The cost required
to show a small, but signiﬁcant, effect on top of back-
ground medical therapy can be in the hundreds of
millions of dollars (9). Last, these trials consist of pa-
tients with substantial phenotypic heterogeneity.SEE PAGE 1765In this issue of the Journal, Ahmad et al. (10)
described a cluster analysis that identiﬁed 4 distinct
phenotypes of HFrEF patients enrolled in the
HF-ACTION (Heart Failure: A Controlled Trial In-
vestigating Outcomes of Exercise Training) study.*Editorials published in the Journal of the American College of Cardiology
reﬂect the views of the authors and do not necessarily represent the
views of JACC or the American College of Cardiology.
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disclose.HF-ACTION was designed to assess the impact of
an exercise program on HF outcomes in patients with
an ejection fraction of #35%, who were in New York
Heart Association (NYHA) functional classes II to IV.
Forty-ﬁve baseline clinical variables were selected
by the investigators to perform this analysis. Clusters
were then identiﬁed on the basis of similarities or
differences in measured characteristics, with strong
associations among members of the same cluster and
weak associations among members of other clusters.
The clusters identiﬁed with this analysis followed
different clinical courses, as demonstrated by the
diverse mortality and hospitalization rates among
the groups. The largest group, Cluster 1, included
predominantly elderly Caucasian men with ischemic
cardiomyopathy. This cluster exhibited a high burden
of comorbidities, advanced disease found by tradi-
tional measures (such as peak oxygen consumption
[VO2], N-terminal pro–B-type natriuretic peptide
[NT-proBNP], and 6-min walk distance), and the
highest mortality rate. Cluster 2 patients were the
youngest on average, largely African Americans with
nonischemic cardiomyopathy, and had overall milder
disease, as well as high hospitalization rates and a
lower mortality overall. Although Cluster 3 patients
displayed similar demographic characteristics and
disease severity to Cluster 1, they had more anginal
symptoms. These patients had high rates of hospi-
talization, but they had a lower mortality than Clus-
ter 1. With a higher percent of women than other
clusters, Cluster 4 patients were largely Caucasian
with nonischemic disease in etiology and had a lower
burden of comorbidities. This cluster experienced
the lowest rates of mortality and hospitalization.
Perhaps most interestingly, these clusters differed
not only in their rates of hospitalization and mortality,
but also appeared to have different responses
to exercise training. Clusters 2 and 3 had signiﬁcant
improvements in peak VO2, whereas the other clusters
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1776did not. The p values for interaction by cluster on the
composite endpoints of cardiovascular (CV) death
and/or CV hospitalization or CV death and/or HF hos-
pitalization were signiﬁcant. Clusters 1 and 2 had a 12%
to 30% risk reduction from exercise training in the CV
death and/or CV hospitalization endpoint, whereas the
other clusters exhibited nonsigniﬁcant effect sizes.
Ahmad et al. (10) should be commended for
this novel and hypothesis-generating work. To our
knowledge, this is the ﬁrst application of a cluster
analysis to identify clinical phenotypes from a large
cohort of patients with HFrEF. Cluster analysis has
successfully deﬁned clinical phenotypes in other
complex diseases (11,12); however, this study demon-
strates that a larger degree of variability exists with-
in the HFrEF population than has been previously
described. The heterogeneity of the effect of a clinical
intervention seen in this analysis may change the
way we think about designing future clinical trials.
Furthermore, this trial shows that grouping patients
who have different background rates of hospitaliza-
tion, different disease severity, and different patho-
physiology may not be appropriate. In addition, the
divergence in hospitalization rates and mortality even
within a single cluster underscores how problematic
composite endpoints can be in clinical trial design.
Although these results are intriguing, several fac-
tors merit consideration before applying them in clin-
ical practice. This cluster analysis, in the words of the
investigators, is meant to be hypothesis-generating.
The selection of the 4 phenotypes and the 45 vari-
ables used for the cluster analysis was somewhat
arbitrary. Because the cluster analysis included vari-
ables that reﬂect disease severity, it is not surprising
that these subgroups displayed different mortality
rates. Conceivably, the same survival curves couldhave been created with a predictionmodel on the basis
of age andNT-proBNP alone. The clusters studiedwere
also identiﬁed in a single clinical trial, which predom-
inantly included white men with ischemic cardiomy-
opathy. Even Cluster 4, which was identiﬁed as the
female cluster, was predominantly male (59%). In
addition, patients who enter into trials represent a
select population within the larger group of patients
with disease. Hence, the distinctive phenotypes iden-
tiﬁed in this study need further validation in larger,
external, population-based cohorts of HFrEF patients
(13). The conﬁdence intervals for the effect of exercise
training on the composite endpoints by cluster were
wide, so these results need to be interpreted with
caution. Because a large number of hypotheses were
tested, the apparent increase in harm with exercise
training in Cluster 4 may have been due to chance.
In summary, this study demonstrates signiﬁcant
heterogeneity within a cohort of HFrEF patients who
have different clinical characteristics, outcomes, and
response to therapy. Perhaps it is time to move away
from a classiﬁcation system based on ejection fraction
and subjective symptom severity alone. Pairing phe-
notypes identiﬁed with cluster analyses with an
“omics” approach (genomics, metabolomics, and pro-
teomics) may allow for a more advanced classiﬁcation
scheme on the basis of the underlying biology. This
could set the stage for more rational clinical trial de-
signs for HFrEF going forward, which is likely neces-
sary in today’s era of background medical therapy.
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